Valbenazine and deutetrabenazine are described as being more effective with low-potency agents and are usually transient at initiation.

• A. Valbenazine and deutetrabenazine are more with low-potency agents, at initiation, dose increases. Usually transient.
• B. Valbenazine and deutetrabenazine are only used with high-potency agents; no dose initiation changes.
• C. Valbenazine and deutetrabenazine have no relation to potency.
• D. Valbenazine and deutetrabenazine are antidepressants.

Answer: (A)

VMAT2 inhibitors like valbenazine and deutetrabenazine treat tardive dyskinesia by decreasing dopamine release in nerve terminals, which helps reduce involuntary movements. Because patients can be sensitive to dose changes and to dopaminergic effects, the usual approach is to start at a low dose and slowly increase it (initiation with titration). When the TD is related to low-potency antipsychotics, these agents tend to show greater benefit, since those drugs carry a higher risk and burden of TD, making the VMAT2 inhibitors particularly helpful in that context. Early in treatment, you may see only modest improvement or a transient fluctuation in symptoms as the dose is adjusted, but as the dose stabilizes, symptom control generally improves. They are not antidepressants, and their relevance to potency is about TD management across different antipsychotics, with a note that initiation and titration are key to achieving tolerability and effectiveness.